Robert S Brown
Overview
Explore the profile of Robert S Brown including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
80
Citations
1367
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
3.
Alqahtan S, Brown R
Gastroenterol Hepatol (N Y)
. 2023 Mar;
19(1):20-29.
PMID: 36865816
Obesity has become a global epidemic, adding to the burden of chronic diseases and disabilities. Metabolic syndrome, especially obesity, is a significant risk factor for nonalcoholic fatty liver disease, which...
4.
Blach S, Brown K, Brown R, Gholam P, Terrault N, Estes C, et al.
J Infect Public Health
. 2022 Dec;
16(1):64-70.
PMID: 36473359
Background: As of 2019, the United States (US) was not on track to achieve targets for elimination, due to increasing incidence and treatment barriers. In 2020, the COVID-19 pandemic disrupted...
5.
Izzy M, Brown R, Eguchi S, Hwang S, Matamoros M, Quintini C, et al.
Clin Transplant
. 2022 May;
36(10):e14680.
PMID: 35502664
Background: While preoperative physiologic evaluation of live liver donors is routinely performed to ensure donor safety and minimize complications, the optimal approach to this evaluation is unknown. Objectives: We aim...
6.
Raines N, Ganatra S, Nissaisorakarn P, Pandit A, Morales A, Asnani A, et al.
Kidney360
. 2022 Apr;
2(1):33-41.
PMID: 35368823
Background: AKI is a significant complication of coronavirus disease 2019 (COVID-19), with no effective therapy. Niacinamide, a vitamin B3 analogue, has some evidence of efficacy in non-COVID-19-related AKI. The objective...
7.
Cullaro G, Rubin J, Fortune B, Crawford C, Verna E, Hsu C, et al.
Dig Dis Sci
. 2021 Jul;
67(7):3426-3435.
PMID: 34292470
Background And Aims: Kidney dysfunction is associated with increased mortality among patients with cirrhosis. We investigated whether kidney dysfunction types [e.g., acute kidney injury (AKI), chronic kidney disease (CKD), and...
8.
Zhuo M, Yang D, Goldfarb-Rumyantzev A, Brown R
J Hypertens
. 2021 Jul;
39(11):2250-2257.
PMID: 34232158
Objectives: Hypertension is a risk factor for chronic kidney disease (CKD) progression and mortality. However, the optimal blood pressure associated with decreased mortality in each stage of CKD remains uncertain....
9.
Arab J, Diaz L, Baeza N, Idalsoaga F, Fuentes-Lopez E, Arnold J, et al.
J Hepatol
. 2021 Jun;
75(5):1026-1033.
PMID: 34166722
Background & Aims: Corticosteroids are the only effective therapy for severe alcohol-associated hepatitis (AH), defined by a model for end-stage liver disease (MELD) score >20. However, there are patients who...
10.
Salerno D, Thornberg M, Lange N, Hedvat J, Robbins H, Brown R, et al.
Clin Transplant
. 2021 Jun;
35(12):e14396.
PMID: 34165845
Background: The purpose of this study was to evaluate outcomes of bleeding and thrombosis resulting from the use of direct oral anticoagulants (DOACs) in a large cohort of solid organ...